On June 27, 2023, Paratek Pharmaceuticals, Inc. acknowledged receipt of a letter from NexPoint Asset Management, L.P. The Company stated that it appreciates receiving constructive feedback from its stockholders and as such, has actively engaged with NexPoint Asset Management over the past several months. The Company added that however, its board of directors respectfully disagrees with NexPoint Asset Management’s characterizations contained in its letter. The Company also stated that it looks forward to providing stockholders with additional details with respect to the previously announced acquisition of the Company by Gurnet Point Capital and Novo Holdings A/S when it files its proxy materials with the Securities and Exchange Commission.